Taken together, these findings suggest that knockout of SREBP1c attenuates cisplatin‐induced YME1L1 inhibition, mitochondrial dysfunction, AKI and its progression to CKD in vivo. This evidence concerns the gene YME1L1 and chronic kidney disease.